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Introduction: Strategies for biological repair and regeneration of the intervertebral disc (IVD) by cell and tissue
engineering are promising, but few have made it into a clinical setting. Recombinant human bone morphogenetic
protein 7 (rhBMP-7) has been shown to stimulate matrix production by IVD cells in vitro and in vivo in animal
models of induced IVD degeneration. The aim of this study was to determine the most effective dose of an
intradiscal injection of rhBMP-7 in a spontaneous canine IVD degeneration model for translation into clinical
application for patients with low back pain.
Methods: Canine nucleus pulposus cells (NPCs) were cultured with rhBMP-7 to assess the anabolic effect of rhBMP-7
in vitro, and samples were evaluated for glycosaminoglycan (GAG) and DNA content, histology, and matrix-related
gene expression. Three different dosages of rhBMP-7 (2.5 μg, 25 μg, and 250 μg) were injected in vivo into early
degenerated IVDs of canines, which were followed up for six months by magnetic resonance imaging (T2-weighted
images, T1rho and T2 maps). Post-mortem, the effects of rhBMP-7 were determined by radiography, computed
tomography, and macroscopy, and by histological, biochemical (GAG, DNA, and collagen), and
biomolecular analyses of IVD tissue.
Results: In vitro, rhBMP-7 stimulated matrix production of canine NPCs as GAG deposition was enhanced, DNA
content was maintained, and gene expression levels of ACAN and COL2A1 were significantly upregulated. Despite
the wide dose range of rhBMP-7 (2.5 to 250 μg) administered in vivo, no regenerative effects were observed at
the IVD level. Instead, extensive extradiscal bone formation was noticed after intradiscal injection of 25 μg and
250 μg of rhBMP-7.
Conclusions: An intradiscal bolus injection of 2.5 μg, 25 μg, and 250 μg rhBMP-7 showed no regenerative effects
in a spontaneous canine IVD degeneration model. In contrast, intradiscal injection of 250 μg rhBMP-7, and to a
lesser extent 25 μg rhBMP-7, resulted in extensive extradiscal bone formation, indicating that a bolus injection of
rhBMP-7 alone cannot be used for treatment of IVD degeneration in human or canine patients.* Correspondence: M.A.Tryfonidou@uu.nl
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Low back pain is one of the major causes of disability in
humans [1]. Several studies have provided evidence for
its association with intervertebral disc (IVD) degeneration
[2,3]. Current therapies, such as physiotherapy, anti-
inflammatory medications, and surgery alleviate symptoms,
but do not restore the physiological function of the degen-
erated IVD. Prevention of further degeneration or regener-
ation of the IVD requires intervention at an early stage.
Strategies for biological repair and regeneration of the IVD
by cell and tissue engineering are promising, but are not
widely clinically applicable thus far. A number of studies
have been performed on bone morphogenetic proteins
(BMPs), given their potential regenerative role in degenera-
tive IVD disease [4]. BMPs belong to the transforming
growth factor-β (TGF-β) superfamily and are involved in
many developmental processes [4,5]. Recombinant human
bone morphogenetic protein 7 (rhBMP-7) has been tested
extensively and appears to be a promising BMP for IVD re-
generation [6-8], as it has been shown to have beneficial ef-
fects on extracellular matrix production of rabbit, bovine,
and human IVD cells in vitro [7,9-13]. Several animal
models with experimental IVD degeneration were used to
study the efficacy and translational aspects of BMP-7 to-
wards a clinical application in humans [14]. In rabbits with
induced IVD degeneration, rhBMP-7 restored disc height
and improved the IVD viscoelastic properties by increasing
the proteoglycan content [15,16]. An anti-catabolic effect
of rhBMP-7 was shown in a rat model with induced IVD
degeneration [17]. Also in a canine model of allogenic IVD
transplantation, nucleus pulposus cells (NPCs) expressing
rhBMP-7 prevented degeneration of the transplanted IVD
at six months follow-up [18]. Thus far, novel regenerative
therapies involving intradiscal administration of rhBMP-7
have been tested in animal models with induced IVD de-
generation, but not in an animal model with spontaneous
IVD degeneration that more closely resembles the bio-
logical condition in humans. Furthermore, dose response
studies evaluating intradiscal injection of rhBMP-7 and its
possible adverse effects are not available [4,19].
The goal of this study was to assess the effect of a wide
range of doses of intradiscal injections of rhBMP-7 (2.5
to 250 μg) in a canine model with spontaneous IVD de-
generation that closely resembles human IVD degener-
ation and disease [20,21]. For this, we first investigated
the anabolic effect of two dosages of rhBMP-7 on early
degenerated canine NPCs in vitro. Potential regenerative
effects of rhBMP-7 in vivo were studied by obtaining
conventional T2-weighted images and T2 and T1ρ maps
in a longitudinal manner. Both T1ρ and T2 relaxation
times are correlated with IVD degeneration since T2
relaxation times correlate strongly with water content,
while T1ρ relaxation times are particularly sensitive to a
decrease in glycosaminoglycan (GAG) content in the NP[22,23]. At six months follow-up, the effects of rhBMP-7
were determined post-mortem by radiography, computed
tomography, and macroscopy, and by histological, bio-
chemical, and biomolecular analyses.
Methods
Ethics statement
All procedures involving animals were approved and con-
ducted in accordance with the guidelines set by the Animal
Experiments Committee (DEC) of Utrecht University (ex-
perimental numbers: 2012.III.07.065, 2013.III.02.017, and
2013.II.12.126), as required by Dutch regulation.
Isolation and culture of nucleus pulposus cells
NP tissue was separated from early degenerated IVDs
(Pfirrmann grade 2) of 12 laboratory beagle dogs; care
was taken to avoid the transitional zone. Tissue was
washed with high-glucose (hg)-DMEM +GlutaMAX™ +
pyruvate (31966, Invitrogen, Paisley, UK) + 1% penicillin/
streptomycin (p/s) (P11-010, PAA Laboratories GmbH,
Piscataway, NJ, USA), and digested with 0.15% pronase
(11459643001, Roche Diagnostics, IN, USA) for 45 mi-
nutes at 37°C, and subsequently digested overnight with
0.15% collagenase II (4176, Worthington, Lakewood, NJ,
USA) at 37°C. NPCs were filtered over a 70-μm filter,
centrifuged (5 minutes at 500 g), and cryopreserved at
passage 0 (hg-DMEM+GlutaMAX+ 10% dimethyl sulf-
oxide (DMSO) + 10% fetal bovine serum (FBS) (high per-
formance 16000–044, Gibco, Bleiswijk, The Netherlands))
until further use. NPCs were expanded in expansion
medium (hg DMEM+GlutaMAX+ pyruvate (Invitrogen),
10% FBS, 1% p/s, 20 mM ascorbate-2-phosphate (A8960,
Sigma-Aldrich, Saint Louis, MO, USA), 0.02 mM dexa-
methasone (D1756, Sigma-Aldrich), 1 ng/ml basic fibro-
blast growth factor (bFGF) (PHP105, AbD Serotec,
Oxford, UK), and 0.5% Fungizone (15290–018, Invi-
trogen) in 175-cm2 cell culture flasks (660175, Greiner
bio-one, Cellstar, Alphen aan den Rijn, The Netherlands)
until passage 2 (P2).
Cells (P2) were pooled to yield 5 different NPC donor
groups and pelleted in ultra-low attachment 96-well
plates (Corning Costar 7007, Sigma-Aldrich) by centri-
fugation at 185 g for 8 minutes. Each pellet contained
200,000 NPCs and was cultured in 200 μl chondrogenic
culture medium for 28 days (5% CO2, 20% O2). Standard
chondrogenic medium (hg-DMEM +GlutaMAX (Invi-
trogen), was supplemented with 1% insulin-transferrin-
selenium (ITS) + premix (354352 Corning, Tewksbury,
MA, USA), 20 mg/ml proline (P5607 Sigma-Aldrich),
1% p/s, 0.5% Fungizone, 0.02 mM dexamethasone, and
20 mM ascorbate-2-phosphate), and remained untreated
(negative control) or was supplemented with 10 or 100 ng/
ml rhBMP-7 (mammalian cell derived; 354-BP-010 R&D
Systems Europe Ltd, Oxon, UK). Media were renewed
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analysis of GAG content.
Glycosaminoglycan and DNA content of nucleus pulposus
cell pellets and glycosaminoglycan content of culture
media
At days 7 and 28, two NPC pellets per donor and condition
were digested overnight at 60°C in papain (250 μg/ml pa-
pain (P3125, 100 mg, Sigma-Aldrich) + 1.57 mg cysteine
HCL (C7880, Sigma-Aldrich)). The 1,9-dimethylmethylene
blue (DMMB) assay was used to quantify GAG content
[24] of the pellets and media. GAG concentrations were
calculated by using chondroitin sulfate from shark cartilage
(C4384, Sigma-Aldrich) as a standard and the absorbance
was read at 540/595 nm. The Quant-iT™ dsDNA Broad-
Range assay kit in combination with a Qubit™ fluorometer
(Invitrogen) was used in accordance with the manufac-
turer’s instructions to determine the DNA content of
the NPC pellets.
RNA isolation and quantitative RT-PCR of nucleus pulposus
cell pellets
At days 7 and 28, RNA was isolated from two pellets per
donor and condition and pooled. After crushing the pellets
with a pellet pestle (9951–901, Argos Technologies, Elgin,
IL, USA), total RNA was isolated by using the RNeasy Mi-
cro Kit according to the manufacturer’s instructions. After
on-column DNase-I digestion (RNase-free DNase kit;
Qiagen, Venlo, The Netherlands), RNA was quantified by
using a NanoDrop 1000 spectrophotometer (Isogen Life
Science, IJsselstein, The Netherlands). The iScript™ cDNA
Synthesis Kit (Bio-Rad, Veenendaal, The Netherlands) was
used to synthesize cDNA.
Quantitative PCR (qPCR) was performed using an iCy-
cler CFX384 Touch thermal cycler, and IQ SYBRGreen
Super mix (Bio-Rad). qPCR was performed to assess the
effects of rhBMP-7 at gene expression levels on: 1) extra-
cellular matrix anabolism (aggrecan (ACAN), collagen type
2 alpha 1 (COL2A1), collagen type 1 alpha 1 (COL1A1)), 2)
proliferation (cyclin-D1 (CCND1)), 3) extracellular matrix
catabolism (a disintegrin and metalloproteinase with
thrombospondin motifs (ADAMTS5), matrix metallopro-
teinase 13 (MMP13), tissue inhibitor of metalloproteinase
1 (TIMP1)), 4) apoptotic markers (B-cell lymphoma 2-
associated X (BAX), B-cell lymphoma 2 (BCL2), caspase
3 (CASP3)), and 5) BMP signaling (BMP receptor 1A
(BMPR1A), BMP receptor 1B (BMPR1B), BMP receptor
2 (BMPR2), inhibitor of DNA binding 1 (ID1), noggin
(NOG)).
Details on the primer pairs employed are given in
Additional file 1. All dog-specific primers were designed
in-house using Perlprimer [25], except for MMP13 [26].
Primer specificity was evaluated with BLAST, and the
designed amplicon was tested for secondary structuresusing MFold [27]. Primers were purchased from Euro-
gentec (Maastricht, The Netherlands). Amplification effi-
ciencies ranged from 86 to 119%. Relative expression
levels were determined by the efficiency-corrected delta-
delta CT (ΔΔCt) method. Ct values of each target gene
were normalized by the mean Ct value of four reference
genes (ΔCt), that is, glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH), ribosomal protein S19 (RPS19),
succinate dehydrogenase complex, subunit A, flavoprotein
variant (SDHA), and hypoxanthine-guanine phosphoribo-
syltransferase (HPRT), whereas the mean Ct of all condi-
tions for each target gene was used as a calibrator (ΔΔCt).
Histopathological evaluation of nucleus pulposus cell pellets
Safranin-O/fast green staining was performed to evaluate
the presence of GAG deposition at a histopathological
level. Two pellets per donor and condition were fixed
overnight in neutral buffered formaldehyde 4% (Boom BV,
Meppel, The Netherlands) supplemented with 1% eosin
(115935, Merck, Schiphol-Rijk, The Netherlands). Sub-
sequently, the pellets were embedded in alginate and
then paraffin. Sections (5 μm) were stained with Mayer’s
hematoxylin (3870, Avantor Performance Materials, Center
Valley, PA, USA), safranin-O (58884, Sigma-Aldrich) and,
as a counterstaining, fast green (F7252, Sigma-Aldrich).
Experimental animals
Seven intact male beagle dogs with a median age of
1.3 years (range: 1.1 to 1.8) and a median weight of
11.7 kg (range: 10.2 to 12.8) were purchased from Harlan
(Gannat, France). All dogs underwent a general, ortho-
pedic, and neurologic examination by a board-certified
veterinary surgeon (BM). The study was set up following a
randomized block design. Single bolus injections of 2.5 μg,
25 μg, and 250 μg rhBMP-7 (mammalian cell derived,
CYT-276, ProSpec-Tany TechnoGene Ltd, Ness-Ziona,
Israel), and a sucrose buffer (sham) were injected into the
NPs in the T13-S1 spinal segments in a balanced Latin
square design. IVDs adjacent to those injected with 250 μg
of rhBMP-7 remained untreated. Preliminary studies in
cadaveric spines showed that a volume of 40 μl could be
injected into the NP without considerable resistance (Meij BP,
Tryfonidou MA, Willems N). The highest dosage of rhBMP-
7 was constrained by the highest possible concentration that
could be accomplished via dialysis, that is, 250 μg in 40 μl.
Preparation of rhBMP-7 for in vivo application
Prior to the in vivo studies, the biological activity of
rhBMP-7 from different manufacturers was determined
in an alkaline phosphatase (ALP) activity assay in ATDC5
cells, amongst them rhBMP-7 from R&D and ProSpec-
Tany. rhBMP-7 from ProSpec-Tany showed the highest
biological activity, as shown in Additional file 2, and was
further chosen to be employed in the in vivo studies.
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was reconstituted in 60 μl sterile water. This solution
was dialyzed against a buffer solution containing 17% su-
crose, 20% mannitol, 332 mM glycine, and 0.8% Tween
20, using a slide-A-Lyzer dialysis cassette (66454, Thermo
Fisher Scientific Inc., Rockford, IL, USA) with a molecular
weight cutoff of 10 kDa overnight with 4 buffer changes.
The final solution containing 300 μg of rhBMP-7 (calcu-
lated amount) was freeze-dried overnight and reconsti-
tuted in sterile water, to achieve a final concentration of
250 μg rhBMP-7 in 40 μl buffer solution containing 1%
sucrose, 1.2% mannitol, 20 mM glycine, and 0.05% Tween
20. Activity of the dialysate was shown to be retained
in vitro through its capacity to induce ALP production in
mice ATDC5 cells. Additional file 2 shows the biologic ac-
tivity of the dialyzed rhBMP-7 compared with the pre-
dialyzed rhBMP-7.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) of the lumbar verte-
bral column were performed in fully anesthetized dogs
prior to surgery (t0) and at 6 (t6), 12 (t12), and 24 (t24)
weeks after surgery. Dogs were pre-medicated with intra-
venous dexmedetomidine 10 μg/kg intravenously and
butorphanol 0.1 mg/kg, and anesthesia was induced
with a continuous rate infusion of propofol (3 to 4 mg/
kg) and dexmedetomidine 1 μg/kg. A laryngeal mask
was inserted, and anesthesia was maintained with iso-
flurane (2 to 3%) in a 1:1 oxygen/air mixture. Prior to
the first MRI scan, a blood sample was drawn from the
jugular vein to assess white blood cell count and differ-
entiation, to exclude systemic inflammation. MRI was
performed with a 1.5 Tesla scanner using a spine array
coil (Philips Healthcare, Best, The Netherlands). Sagittal
T2-weighted (T2W) images were acquired using a
turbo-spin echo (TSE) pulse sequence with the follow-
ing parameters: repetition time (TR) = 2,557 ms, echo
time (TE) = 100 ms, field of view (FOV) = 200 mm, ac-
quisition matrix = 332 × 306, slice thickness = 2 mm,
number of slices = 13. For T2 mapping, acquisition pa-
rameters were as follows: TR = range 2,000 to 4,000 ms,
TE = 12.5 to 100 ms in 12.5 ms increments, FOV =
250 mm, acquisition matrix = 416 × 200, slice thickness =
2 mm, number of slices = 11. Sagittal T1ρ weighted im-
aging was performed using a spin-lock-prepared sequence
with a three dimensional multi-shot ultrafast gradient
echo (T1-TFE) readout with the following parameters:
TR = 8.3 ms, TE = 4.3 ms, FOV = 250 mm, acquisition
matrix = 416 × 378, slice thickness = 2 mm, number of
slices = 25, TFE factor = 64, flip angle = 10°, shot inter-
val = 2,000 ms. To allow quantitative T1ρ mapping, data
were acquired five times, each with a different spin-lock
time (TSL): 1, 10, 20, 40, and 80 ms. Spin-lock ampli-
tude was set to 500 Hz.T2 and T1ρ quantification
Mid-sagittal slices of T2W images were used to evaluate
the grade of degeneration at all time points. Lumbar
IVDs were assessed by a veterinary radiologist that was
blinded to treatment allocation, according to the Pfirr-
mann classification validated for dogs by Bergknut et al.
[28]. Only lumbar IVDs with a Pfirrmann score II at t0
were included for injection. Disc height index (DHI) was
calculated at all time points on T2W images for each
IVD, according to the method described by Masuda et al.
[15]. In short, DHI was calculated by averaging widths of
the dorsal, middle, and ventral parts of the vertebral disc
and dividing that by the average of dorsal, middle, and
ventral body heights of the adjacent cranial and caudal
vertebrae. To calculate the DHI of L7-S1, the average
body height of only the cranial vertebra (L7) was used,
as S1 has a different shape than the lumbar vertebrae.
For the analysis of T2 and T1ρ values, an oval-shaped
region of interest (ROI) was manually segmented on
mid-sagittal sections, to select NP tissue in each IVD in
the free open-source DICOM viewer Osirix (Pixmeo,
Geneva, Switzerland). ROIs were exported to and analyzed
with Wolfram Mathematica 10.0 (Wolfram Research,
Champaign, IL, USA). T2 and T1ρ values were computed
by calculating the mean signal intensity (S) in each ROI,
and by fitting these intensity data into the following equa-
tions, respectively, using the Levenberg-Marquardt non-
linear least-squares method implemented in Mathematica:
S TEð Þ ¼ S0e‐TSL=T2 ð1Þ
or
S TSLð Þ ¼ S0e‐TE=T1ρ ð2Þ
S0 denotes the equilibrium magnetization, whereas
S(TSL) and S(TE) indicate the T2- and T1ρ-prepared
signals, respectively.
Surgical procedure
The anesthesia protocol for MRI and surgery was identi-
cal. Analgesia was provided pre-operatively by intraven-
ous methadone 0.5 mg/kg and carprofen 4 mg/kg, and
perioperatively by a continuous rate infusion of a combin-
ation of fentanyl (loading dose 10 μg/kg, 15 to 20 μg/kg/
hr) and ketamine (loading dose 0.5 mg/kg, 10 μg/kg/min).
Dogs were positioned in right recumbence to expose and
inject T13-L6 via a left lateral approach, and subsequently
in ventral recumbence to expose and inject L6-S1 via a
dorsal approach. A 100 μl gastight syringe (7656–01
Model 1710 RN) with a 27 G needle (25 mm, 12° beveled
point; Hamilton Company USA, Reno, Nevada, USA) was
used to inject 40 μl of the BMP-7 containing solutions or
control into the NP under magnified vision (3.3×). Loca-
tion of the tip of the needle in the NP was estimated by
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(1 cm), while encountering steady resistance. When the
NP was reached, the resistance decreased and the volume
of 40 μl could be easily injected. The needle was retracted
slowly to allow the AF puncture site to close, and the
site was inspected for extrusion of the administered
compound and rinsed with 0.9% NaCl. Postoperative
pain management in all dogs consisted of intramuscular
methadone 0.3 mg/kg every 6 hours and subcutaneous
carprofen 4 mg/kg once a day during the first 24 hours,
and tramadol 2 to 5 mg/kg administered orally four
times a day, and carprofen 4 mg/kg administered orally
for the following 7 and 10 days, respectively. All dogs
were treated postoperatively with antibiotics (amoxicil-
lin/clavulanic acid 12.5 mg/kg twice a day) for five days.
Dogs were monitored daily throughout the study to as-
sess pain symptoms according to the short form of the
Glasgow composite pain scale [29]. Dogs that showed
signs of pain received carprofen and/or tramadol.
Radiographic imaging and computed tomography
Radiographs and computed tomography (CT) scans of
the T11-S3 segment were obtained postmortem (t24) and
were evaluated by an independent veterinary radiologist
for new bone formation, end plate sclerosis, and disc pro-
trusion (only CT). Lateral and dorsoventral radiographs
were obtained with a digital radiography system (Philips
digital Rad TH, Eindhoven, The Netherlands) using 50 kVp
and 5 mA. Transverse CT images were acquired with a
third-generation single-slice helical CT-scanner (Philips
Secura, Eindhoven, The Netherlands). Contiguous 2-mm
thick slices with 1 mm overlap were obtained from T11-S3
with exposure settings of 120 kV and 260 mA.
Sample collection, macroscopic grading, and
histopathological grading
Dogs were euthanized 24 weeks post-injection by way of
intravenous sedation with dexmedetomidine 0.04 mg/kg,
followed by pentobarbital 200 mg/kg. Subsequently, the
vertebral column (T12-S1) was harvested using an electric
multipurpose saw (Bosch, Stuttgart, Germany). All mus-
cles were removed and the lumbar vertebrae were trans-
ected transversely with a band saw (EXAKT tape saw,
EXAKT Advanced Technologies GmbH, Norderstedt,
Germany), resulting in nine spinal units (½ vertebra - end-
plate - IVD - endplate - ½ vertebra). A diamond band
pathology saw (EXAKT 312 saw; EXAKT diamond cutting
band 0.1 mm D64; EXAKT Advanced Technologies
GmbH, Norderstedt, Germany) was used to transect these
units sagittally into two identical parts. From one part, the
endplate and vertebra were removed with a surgical knife,
and the remaining IVD tissue containing NP and AF, was
snap frozen in liquid nitrogen and stored at −80°C for bio-
chemical and biomolecular analyses. The other part wasphotographed (Olympus VR-340, Hamburg, Germany) for
macroscopic evaluation (Thompson score) and fixed in
50 ml of 4% buffered formaldehyde (Klinipath, Duiven,
The Netherlands) at 4°C for 14 days. Images of the IVD seg-
ments were evaluated blind and in random order by two in-
dependent blinded investigators, according to the Thompson
grading scheme, which has been validated in dogs [30].
Samples were decalcified in 35% formic acid and 6.8%
sodium formate in a microwave oven (Milestone Micro-
wave Laboratory Systems, Sorisole, Italy) overnight at
37°C, for 7 nights and embedded in paraffin [31]. Sections
(5-μm thick) were stained with hematoxylin (109249,
Merck) and eosin (115935, Merck) and with picrosirius red
(saturated aqueous picric acid: 36011, Sigma-Aldrich; sirius
red: 80115, Klinipath)/alcian blue (alcian blue: 05500,
Sigma-Aldrich; glacial acetic acid: 100063, Merck) and
evaluated according to the grading scheme of Bergknut
et al. [21]. Histological sections were scored blind and
in random order by two independent investigators (NW
and SP) using an Olympus BX41 microscope. In case of
disagreement, samples were also scored by a board-
certified veterinary pathologist (GG).
RNA isolation and qPCR of nucleus pulposus and annulus
fibrosus
Cryosections (60-μm thick) of the IVD of the remaining
spinal unit (endplate - IVD) were cut with a cryostat
(Leica CM1800 cryostat, Leica Microsystems Inc.,
Bannockburn, USA) and collected on RNA-se free glass
slides. The NP and AF tissues were separated and half
of the tissues were collected in 400 μl and 750 μl
cOmplete lysis M EDTA-free buffer (Roche Diagnostics
Nederland BV, Almere, The Netherlands), respectively,
and stored at −80°C until biochemical analysis. The other
halves were collected in 300 μl Buffer RLT containing 1%
β-mercapto-ethanol (Qiagen, Venlo, The Netherlands)
and stored at −80°C until biomolecular analysis. Total
RNA was isolated by using the RNeasy Fibrous Tissue
Mini Kit (Qiagen, Venlo, The Netherlands). The incuba-
tion period with proteinase K was reduced to five minutes
to increase RNA yield. RNA quantification and cDNA
synthesis were performed in a similar way as described for
the NPC pellets in vitro. Reference genes and the subset
of target genes were similar to those determined in vitro.
Glycosaminoglycan, DNA, and collagen assays of nucleus
pulposus and annulus fibrosus
To measure GAG and DNA content, the NP and AF
samples were homogenized in cOmplete lysis M EDTA-
free buffer in a TissueLyser II (Qiagen) for 2× 30 seconds
at 20 Hz. The supernatant and pellet of each NP and AF
were digested overnight in papain and measurements
were performed as described in vitro. Collagen was quan-
tified in the pellets of the NP and AF by using a
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overnight, hydrolyzed at 108°C overnight in 4 M NaOH,
centrifuged (15 seconds at 14,000 g) and stored at −20°C.
Prior to measurements, samples were centrifuged (15 sec-
onds at 14,000 g) once more, chloramine T reagent (2426,
Merck) was added, and samples were allowed to shake for
20 minutes at 170 rpm. Freshly prepared dimethylamino-
benzaldehyde (3058 Merck) was added, and samples were
incubated for 20 minutes at 60°C. The absorbance was
read at 570 nm and collagen content was calculated from
the hydroxyproline content by multiplying with a factor
7.5 [32]. DNA and collagen content in the supernatants
were negligible and therefore not included in the calcula-
tions. Total GAG and collagen content were normalized
to DNA content in the sample.Statistical analyses
All data were analyzed by using R statistical software,
package 3.0.2 [33]. Residual plots and quantile-quantile
(Q-Q) plots were used to check normality of the data. In
case of violation, data were logarithmically transformed.
If non-normality remained after transformation, non-
parametric tests were employed.
In vitro, cumulative GAG release, GAG and DNA con-
tent, the GAG/DNA ratio, and ΔCT values for the inves-
tigated target genes, were statistically evaluated by using
the nonparametric Kruskal-Wallis test, followed by the
Mann–Whitney U-test. The effect of the injected treat-
ments in vivo on GAG, DNA and collagen content, DHI,
and T1ρ and T2 values was analyzed with a linear mixed-
effect model. A random effect ‘dog’ (dog one to seven)
was incorporated to capture the correlation between mul-
tiple measurements within one dog. For GAG, DNA, and
collagen analysis, factors incorporated into the model as a
fixed effect were ‘treatment’ (2.5 μg rhBMP-7, 25 μg
rhBMP-7, 250 μg rhBMP-7, and sham), ‘tissue’ (NP and
AF), and their interaction. For DHI analysis ‘treatment’,
‘time’ (t0, t6, t12, and t24), and their interaction served as
fixed effect factors. The Cox proportional hazards regres-
sion model was used to estimate the effect of the injected
treatments on gene expression levels in vivo. Calculations
were performed on the ratio of the CT values for each tar-
get gene to the mean CT value of the reference genes. CT
values of 40 or more were right censored. Regression
coefficients were estimated by the maximum likelihood
method. Model selection was based on the lowest
Akaike Information Criterion (AIC). Differences be-
tween treatments were considered significant if the con-
fidence interval did not include 0, whereas hazard ratios
were considered significant if the confidence interval
did not include 1. For in vitro and in vivo analyses, con-
fidence intervals were calculated and stated at the 99%
confidence level to correct for multiple comparisons.Significant differences and the corresponding confi-
dence intervals are represented in Additional file 3.
Results
Effect of rhBMP-7 on early degenerated canine nucleus
pulposus cell pellets in vitro
Cell maintenance and increased glycosaminoglycan release
and content by rhBMP-7
NPC pellets treated with 10 and 100 ng/ml rhBMP-7
showed a dose-dependent significant increase in cumula-
tive GAG release into the medium compared with the
negative control (Figure 1A). Regardless of the culture
condition, DNA content of the NPC pellets was signifi-
cantly lower compared with DNA content at day 0.
Treatment with 100 ng/ml rhBMP-7 resulted in a sig-
nificantly higher DNA content at day 28 compared with
the negative control and the 10 ng/ml rhBMP-7-treated
NPC pellets (Figure 1B). A significant increase in GAG
content and GAG/DNA at day 28 was shown in the
100 ng/ml rhBMP-7-treated NPC pellets compared with
the negative control and the 10 ng/ml rhBMP-7-treated
NPC pellets. Safranin-O/fast green staining of the NPC
pellets at day 28 showed a higher GAG deposition in the
matrix of the pellets treated with 100 ng/ml rhBMP-7
compared with the negative control and the 10 ng/ml
rhBMP-7-treated pellets (Figure 2).
Pro-anabolic and anti-apoptotic effect of rhBMP-7
Expression of extracellular matrix genes ACAN and
COL2A1 was significantly upregulated at day 7 in the
100 ng/ml rhBMP-7-treated NPC pellets compared with
the negative control and the 10 ng/ml rhBMP-7-treated
NPC pellets (Figure 3A). COL2A1 expression was sig-
nificantly upregulated in the 100 ng/ml rhBMP-7-
treated NPC pellets compared with the negative control
at day 28. Expression of COL1A1 did not differ between
conditions at any time point. Relative expression of the
proliferative marker CCND1 was significantly upregu-
lated in all conditions at day 28 compared with day 7,
while it was also significantly higher in the 100 ng/ml
rhBMP-7-treated NPC pellets at day 7 compared with
the negative control. Furthermore, CCND1 expression
levels were significantly higher in the 10 ng/ml rhBMP-
7-treated NPC pellets at day 28 compared with the
negative control.
Gene expression of the catabolic gene ADAMTS5 was
significantly lower in the 100 ng/ml rhBMP-7-treated
NPC pellets compared with the 10 ng/ml rhBMP-7-
treated NPC pellets at day 28. In the NPC pellets treated
with 10 and 100 ng/ml rhBMP-7, gene expression of the
catabolic gene MMP13 was significantly lower at day 28
compared with day 7. The relative gene expression of
the anti-catabolic gene TIMP1 was significantly higher
in the negative control and 10 ng/ml rhBMP-7-treated
Figure 1 Glycosaminoglycan (GAG) release and GAG, DNA, and GAG/DNA content in cultured nucleus pulposus cells (NPCs) treated with 10 or
100 ng/ml rhBMP-7. A. NPC pellets treated with rhBMP-7 show a significant dose-dependent increase in cumulative GAG release into the medium
compared with the negative control. B. Regardless of the culture condition, DNA content of the NPC pellets was significantly lower compared
with DNA content at day 0 (DNA0; dashed line), indicated by #. NPC pellets treated with 100 ng/ml rhBMP-7 showed a significantly higher
DNA content at day 28 compared with the negative control and the 10 ng/ml rhBMP-7-treated NPC pellets. C, D. A significant increase in
GAG content and GAG/DNA at day 28 was shown in the 100 ng/ml rhBMP-7-treated NPC pellets compared with the negative control and the
10 ng/ml rhBMP-7-treated NPC pellets. Data are expressed as mean ± SD. **Indicates significant difference at a 99% confidence interval (CI);
*indicates significant difference at a 98% CI; # indicates a significant difference at a 99% CI.
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BCL2 ratio in the 100 ng/ml rhBMP-7-treated NPC pellets
was significantly higher at day 28 compared with day 7.
Relative expression of the apoptotic marker CASP3 was
significantly downregulated at day 28 in the 10 and
100 ng/ml rhBMP-7-treated NPC pellets. Altogether, these
results show a stimulatory effect of 100 ng/ml rhBMP-7
on matrix anabolism, which seemed most profound at day
7, and an anti-apoptotic effect, which seemed most pro-
found at day 28.
Intradiscal application of rhBMP-7 in laboratory beagle dogs
No regenerative changes of rhBMP-7 at the intervertebral
disc level on macroscopy and T2-weighted MRI
All dogs recovered uneventfully from surgery and were
ambulant the next day. During the follow-up period, all
dogs were treated with analgesics and antibiotics in
accordance with the protocol described under ‘Surgical
procedure’, and none of the dogs required additional
medication. Before surgery, a total of 63 IVDs were graded
on T2W MR images (t0). All but one IVDs (62 out of 63)were assigned a grade II according to the Pfirrmann sys-
tem, whereas 1 IVD was assigned a grade III. A total of 42
grade II IVDs were injected. In 61 IVDs the Pfirrmann
scores remained unchanged over time. The IVD that was
assigned a grade III at t0 was assigned a grade II at all sub-
sequent time points, and one IVD treated with the sucrose
buffer that was scored a grade II at t0, was re-graded a
Pfirrmann score III. Postmortem, 62 out of 63 IVDs were
assigned a Thompson score grade II, consistent with early
IVD degeneration, whereas 1 IVD, treated with 250 μg
rhBMP-7, was assigned a grade IV.
Extradiscal new bone formation after intradiscal injection of
25 μg and 250 μg rhBMP-7
In one IVD, extensive new bone formation was noted on
the ventral aspect on MRI at 6, 12, and 24 weeks post-
surgery (t6, t12, and t24). Ventral bone formation was noted
on the post-mortem macroscopy in this particular IVD
and in one other. The IVD that was scored a Thompson
grade IV showed rupturing of the dorsal AF, with NP ma-
terial extending into the spinal canal, irregularity of the
Figure 2 Representative histological images of nucleus pulposus cells (NPCs) cultured in pellets for 28 days stained with Safranin-O/fast green.
NPC pellets treated with 100 ng/ml rhBMP-7 showed a positive Safranin-O/fast green staining for glycosaminoglycan (GAG) and an increased size
compared with the negative control and the 10 ng/ml rhBMP-7-treated pellets.
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(Figure 4). CT images of this dog showed symmetric ex-
tensive bulging of the L7-S1 IVD (lumbosacral junction)
that had been injected. In 4 out of 63 IVDs, postmortem
radiographs and CT images revealed marginated extradis-
cal new bone formation ventrally, laterally (left side), and
ventrolaterally (right side), in combination with mild scler-
osis of the underlying bone (Figure 4). These findings were
associated with treatment with 250 μg rhBMP-7 in 3 out
of 42 IVDs, and treatment with 25 μg rhBMP-7 in 1 out
of 42 IVDs. Mineralization was shown on CT images of 2
out of 63 IVDs; one of these IVDs had been injected with
2.5 μg rhBMP-7, whereas the other had not been injected.
DHI, T2 values, and T1ρ values did not show significant
differences between treatments over time.
Anti-apoptotic effect of 250 μg rhBMP-7
All IVDs were evaluated histopathologically according to
the grading scheme according to Bergknut et al. [21].
The median histological grade was 13 (range: 8 to 20)
and there were no significant differences between thetreatments. In the IVD treated with 250 μg rhBMP-7
that was scored a Thompson grade IV, NP material and
fibroblasts were present in the outer AF. Furthermore,
bone formation was confirmed in 2 IVDs treated with
250 μg rhBMP-7. The BAX/BCL2 ratio in the IVDs (NP
and AF) treated with 250 μg rhBMP-7 was significantly
upregulated compared with the IVDs (NP and AF) treated
with the sham and 25 μg rhBMP-7, suggestive of an anti-
apoptotic effect of 250 μg rhBMP-7. Relative gene expres-
sion of CASP3 in the NP was significantly higher than in
the AF in all treatments, indicative of a higher apoptotic
rate in the NP (Figure 5).
No anabolic effects of rhBMP-7 on extracellular matrix
No significant differences in GAG corrected for DNA or
collagen corrected for DNA were found between the treat-
ments in the NP or the AF (Figure 6A). Regardless of the
treatment, GAG/DNA in the NP was significantly higher
than in the AF, consistent with the known physiological
differences in matrix composition at protein level between
the NP and the AF. These physiological differences were
Figure 3 Relative gene expression of relevant target genes in nucleus pulposus cells (NPCs) cultured in pellets at day 7 and 28. A. Anabolic
markers: aggrecan (ACAN), collagen type 2 alpha 1 (COL2A1), cyclin-D1 (CCND1); B. Catabolic markers: a disintegrin and metalloproteinase with
thrombospondin motifs 5 (ADAMTS5), matrix metalloproteinase 13 (MMP13), tissue inhibitor of metalloproteinase 1 (TIMP1); C. Apoptotic markers:
caspase 3 (CASP3), B-cell lymphoma 2-associated X (BAX), and B-cell lymphoma 2 (BCL2) in non-treated (negative control) and 10 and 100 ng/ml
rhBMP-7-treated NPC pellets. Data are expressed as relative expression ± SD, except for the BAX/BCL2 ratio. **Indicates significant difference at a
99% confidence interval (CI); *indicates significant difference at a 98% CI; δ indicates a significant difference at a 97% CI; filled circle indicates a
significant difference at a 96% CI.
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sion levels of COL2A1 were significantly higher in the NP
than in the AF, and the expression levels of COL1A1 were
significantly lower in the NP than in the AF (Figure 6B).
Relative gene expression of anabolic (ACAN, COL2A1,
COL1A1), catabolic (MMP13) and anti-catabolic (TIMP1)
genes did not significantly differ between treatments.
Gene expression of ADAMTS5 and BMP receptors
BMPR1A and BMPR1B were below the detection level
in both the NP and the AF, independent of treatment.
BMP-7 receptor BMPR2, and the downstream target of
the BMP-7 signaling pathway gene ID1, did not signifi-
cantly differ between the treatments. Relative gene ex-
pression of BMP signaling inhibitor NOG varied widely
regardless of the group, and was significantly higher in
IVDs treated with 25 μg compared with 2.5 μg and
sham-treated IVDs; relative gene expression of NOG is
reported in Additional file 4.Discussion
In this study we first showed that 100 ng/ml rhBMP-7 was
biologically active in vitro in canine NPCs isolated from
mildly, spontaneously degenerated IVDs. Treatment with
100 ng/ml rhBMP-7 stimulated matrix production by ca-
nine NPC pellets isolated from degenerated discs, reflected
by a significantly higher expression of ACAN and COL2A1
seen at day 7, and a significant increase in GAG release
and deposition mainly seen at day 28 of culture. Treat-
ment with 10 ng/ml rhBMP-7 showed a significant
increase in GAG release compared with the negative
control, but did not result in increased GAG deposition.
This is most likely due to a suboptimal balance in GAG
and collagen synthesis and breakdown, resulting in an in-
ability to deposit GAGs in the newly formed collagen net-
work. During pellet culture, in the absence of rhBMP-7,
DNA content decreased significantly over time. NPC pel-
lets treated with rhBMP-7 showed preservation of the
Figure 4 Extradiscal bone formation after intradiscal injection of rhBMP-7. Radiography, computed tomography (CT), macroscopy, and histology
of intervertebral discs (IVDs) injected with 2.5 μg (A), 25 μg (B), and 250 μg (C, D) rhBMP-7. A. Unremarkable findings after injecting 2.5 μg
rhBMP-7 into the IVD. The histological image shows a typical example of an early degenerated NP, consisting of clusters of chondrocyte-like
cells. B. On the left lateral site of the vertebral column extradiscal new bone formation is shown on the radiograph and CT image (white arrow)
next to the IVD injected with 25 μg rhBMP-7. Histology was consistent with early degenerative changes in the IVD as shown in A. C. Extradiscal
new bone formation ventrally of the vertebral column and sclerosis of the ventral vertebral cortex is shown on radiography (white arrow), CT,
macroscopy, and histology (**) after injecting 250 μg rhBMP-7 into the IVD. D. Rupturing of the dorsal AF and protrusion of NP material into
the spinal canal (black arrow) on CT, macroscopy and histology image of an IVD injected with 250 μg rhBMP-7. Irregularity of the endplates
and focal sclerosis in the subchondral bone (white arrowheads) was seen on macroscopy and confirmed on histology (not shown in this image).
AF = annulus fibrosus, EP = endplate, F = facet joint, I = ilium, L = lumbar vertebra, NP = nucleus pulposus, S = sacral vertebra, SC = spinal cord,
Tr = transverse process.
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tion of the biomolecular proliferative marker CCND1
limited to day 7, and a significant downregulation of the
pro-apoptotic marker CASP3 and an increase of the BAX/
BCL2 ratio at day 28. Our findings are consistent with the
pro-anabolic and anti-apoptotic properties of rhBMP-7
that have been shown in vitro in NP cells of different spe-
cies, such as bovine, rabbit, and human [8,12,13,34,35].
Next, we aimed at determining the safe and optimal re-
generative dose of rhBMP-7 for intradiscal application in a
spontaneous canine disc degeneration model. However,
intradiscal injection of a wide dose range of rhBMP-7 (2.5
to 250 μg) did not result in regeneration of the canine
IVD. In contrast to what has been described in rabbitmodels, extracellular matrix production in the NP and the
AF did not differ between treatments. It should be noted
that our data analysis is limited by the absence of wet
weight data for the samples, and that the necessary correc-
tion for DNA content might have leveled out the effects
between treatments. However, DHI, T2, and T1ρ maps
and histological grading did not differ between treatments,
confirming the biochemical data and corroborating the
absence of a regenerative effect after intradiscal applica-
tion of a wide range of dosages of rhBMP-7. Contrasting
findings between the current canine model based on
spontaneous degeneration and the canine models or
rabbit models of induced IVD degeneration, are most
likely related to differences in disc size and cell types
Figure 5 Relative gene expression of genes associated with apoptosis. Relative gene expression of caspase 3 (CASP3), B-cell lymphoma 2-associated
X/B-cell lymphoma 2 (BAX/BCL2) ratio in the nucleus pulposus (NP) (open bars) and the annulus fibrosus (AF) (filled bars) injected with a sucrose buffer
(sham), 2.5 μg, 25 μg, or 250 μg rhBMP-7, were indicative of an anti-apoptotic effect of 250 μg rhBMP-7. The sham-treated NP was used as a reference
and was set at 1 (dashed line). Data are expressed as n-fold change ± SD. ** Indicates a significant difference at a 99% confidence interval (CI); filled
circle indicates a significant difference at a 96% CI.
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differences in genetic background may play a role, with
a concomitant difference in degenerative, as well as re-
generative pathways. Notochordal cells (NCs) are
thought to play a key role in regeneration [36]. In rab-
bits, NCs are retained in the NP at least until 12 monthsFigure 6 Relative gene expression of matrix-related target genes and DNA
discs (IVDs) injected with rhBMP-7. A. GAG/DNA and collagen/DNA did not
pulposus (NP) (open bars) was significantly higher than in the annulus fibro
alpha 1 (COL2A1) and collagen type 1 alpha 1 (COL1A1) did not significantl
were significantly higher in the NP than in the AF, whereas the expression
GAG/DNA and collagen/DNA are expressed as mean ± SD, and COL2A1 and
at a 99% confidence interval (CI).of age, while in humans NCs are lost before 10 years of
age, and in chondrodystrophic dogs, such as beagles, be-
fore one year of age [37]. Although induction of rabbit
IVD degeneration by trauma is accompanied by an in-
flammatory response and ultimately results in decreased
amounts of extracellular matrix, a clear loss in disc, glycosaminoglycan (GAG), and collagen content in intervertebral
significantly differ between the treatments. GAG/DNA in the nucleus
sus (AF) (filled bars). B. Relative gene expression of collagen type 2
y differ between treatments. Gene expression levels of COL2A1
levels of COL1A1 were significantly lower in the NP than in the AF.
COL1A1 as relative expression ± SD. **Indicates a significant difference
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and fibroblast-like cells, the persistence of NCs cannot
be ruled out.
Nevertheless, early degenerated canine NP cells in cul-
ture respond in a similar way to rhBMP-7 as rabbit NP
cells, also suggestive of differences in rhBMP-7 activity
in vitro and in vivo in the canine model. The anabolic
and anti-apoptotic effect of rhBMP-7 on the tissue cells
is mediated via specific BMP receptors that activate the
intracellular signaling protein SMAD1/5/8. The latter
then forms a complex with SMAD4, and the complex
translocates into the nucleus and regulates the transcrip-
tion of target genes. BMP-7, in addition, upregulates
natural BMP antagonists such as NOG that block the
binding sites of the BMP receptors, thereby bringing
rhBMP-7 in an inactive state [38]. Relative gene expres-
sion of NOG was significantly upregulated in IVDs
treated with 25 μg versus 2.5 μg and sham-treated IVDs,
indicating that BMP antagonists may indeed play a role
in the regulation of in vivo BMP-7 signaling. Given that
the BMP signaling pathway is complicated, we can only
speculate on the possible confounding effects limiting
the biological effect of rhBMP-7 in vivo after six months
of follow-up, including availability of BMP receptors, ac-
tivity of NOG, and the presence and ability of proteases
in the degenerated IVD to degrade rhBMP-7. Another
explanation for the differences in vitro and in vivo was
the addition of rhBMP-7 biweekly in vitro, while a single
dose was applied intradiscally in vivo. Protein activity
in vivo is likely to be lost quickly due to a short bio-
logical half-life and diffusion out of the tissue [39]. The
bioavailability of rhBMP-7 in vivo could be increased by
using controlled-release systems, such as hydrogels or mi-
crospheres which allow a sustained release of rhBMP-7
over a prolonged period of time, or by vector-mediated
introduction of BMP-7 encoding genes.
Strikingly, mild to severe extradiscal new bone forma-
tion was seen after intradiscal administration of 25 μg
and 250 μg rhBMP-7 in our canine model. Induction of
bone formation requires three essential components: an
osteo-inductive signal, a substratum, and interactive host
cells. The surgical procedure, associated with tissue injury,
might have provided the chemotactic stimulus for the re-
cruitment of required mesenchymal precursor cells. The
application of rhBMP-7 might have provided the osteo-
inductive stimulus for chondro-osteogenic differentiation,
resulting in ectopic bone formation. Although suboptimal
delivery of BMP-7 by our injection technique might have
played a role, the rhBMP-7 might also have diffused out of
the NP. This phenomenon was also previously described
in a rabbit model, in which osteophyte formation was in-
duced by intradiscal injection of labelled mesenchymal
stem cells [40]. Diffusion of rhBMP-7 out of the IVD may
have been enhanced by biomechanical forces and/ordisorganization of the lamellar structure of the AF that are
part of the early IVD degeneration process [2]. Various
dosages of rhBMP-7, ranging from 0.005 μg to 2 mg, with
or without a carrier, have been reported to induce endo-
chondral bone formation in extraskeletal sites (muscle,
subcutis, tendon, thyroid cartilage, and subdural space)
and in several species (for example, baboons, rats, and
dogs) [6,41-44]. In all these studies, the microenvironment
appeared to be an essential component in tissue regener-
ation. Indeed, rhBMP-7 is approved for the treatment of
non-unions of long bones and the pelvis, and for posterior
lumbar fusion in humans [45]. rhBMP-7 is frequently used
in humans, however, adverse effects, such as ectopic bone
formation, are only occasionally reported [45-47]. Based
on statements of researchers in reviews from 2008 and
2011, a multicenter clinical trial in the United States was
started, in which BMP-7 was intradiscally injected into hu-
man patients with degenerative disc disease [48,49]. How-
ever, results have not yet been published.
Conclusions
An anabolic effect of rhBMP-7 on extracellular matrix
production of canine NPCs isolated from early degener-
ated IVDs was shown in vitro. Despite intradiscal adminis-
tration of a wide dose range of rhBMP-7 (2.5 to 250 μg) in
spontaneous early degenerated canine IVDs, we did not
observe regenerative effects at the IVD level. In fact, injec-
tion of 250 μg rhBMP-7 and, to a lesser extent 25 μg
rhBMP-7, resulted in extensive extradiscal bone forma-
tion. Altogether, this study indicates that additional issues
need to be addressed before intradiscally applied rhBMP-7
can be translated into a clinical application to treat low
back pain in human and canine patients.
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Additional file 1: Primers used for quantitative PCR.
Additional file 2: Biological activity of recombinant human BMP-7.
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Additional file 3: Significant differences and the corresponding
confidence intervals. Tables S1 and S2 represent significant differences
and confidence intervals of statistical analyses performed on in vitro and
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Additional file 4: Relative gene expression of noggin in IVDs
injected with rhBMP-7.
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